Close Menu

Somalogic

By Adam Bonislawski
Biodesix said this week that it is collaborating with pharma firm Kadmon on a 620-patient Phase III clinical trial of that company's reversible tyrosine kinase inhibitor KD019.

By Adam Bonislawski
Scientists at the Forsyth Institute, Beth Israel Deaconess Medical Center, and biomarker firm Quanterix announced this week a collaboration to evaluate protein biomarkers for tuberculosis.

The Bill & Melinda Gates Foundation's Grand Challenges in Global Health program this week awarded ten grants totaling $7.7 million for research into biomarkers for tuberculosis.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

The companies will partner on two clinical studies in dementia that combines Wavi's electroencephalogram-based biomarkers and SomaLogic's blood-based protein biomarkers.

SomaLogic will provide New England Biolabs with protein-binding reagents for use in NEB's nucleic acid amplification and PCR products.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.